Heidi invests in Blackbird
Funding Provisional 90% confidence first seen
Heidi (Heidi Health Trading Pty Ltd.), a health AI startup, raised $340 million in total funding to expand its “AI Care Partner” for healthcare providers. The round included a $100 million Series C led by Blackbird (with participation from Phoenix Court, Point72 Private Investments, and Headline) at a reported $900 million valuation, plus $240 million in growth investment from General Catalyst’s Customer Value Fund. The company said the capital will support deeper adoption and deployment of its AI agents across health systems globally, including further regulatory work for advanced clinical features in Europe and the UK.
The deal
Heidi $340 million Series C · announced 22 Sep 2026
Deal terms as reported in the coverage below.
Decision brief
- What changed
- Heidi, an Australian health AI startup, raised $340 million in combined financing: a $100 million Series C led by Blackbird and $240 million in growth investment from General Catalyst’s Customer Value Fund. The company said it will use the capital to expand its AI Care Partner globally, including doubling headcount in DACH, building a German leadership team, and funding regulatory work for advanced clinical features in Europe and the UK.
- Why it matters
- This financing gives Heidi resources to accelerate go-to-market and deployment in European healthcare markets, especially DACH, which may increase competitive pressure for health AI vendors and create a better-capitalized partner option for providers. For decision-makers in healthcare and adjacent technology businesses, the explicit allocation toward regional hiring and regulatory work signals that market entry in Europe will depend not just on product capability but on local execution and compliance readiness.
- Evidence
- The provided coverage from Trending Topics EU reports the combined $340 million funding, the reported $900 million valuation, Blackbird’s lead role in the Series C, and Heidi’s stated plans for DACH expansion and European/UK regulatory work. Because only one article is provided, the core facts are singly sourced rather than independently corroborated across multiple outlets.
- What remains uncertain
- The coverage does not verify timing, milestones, or expected commercial impact of Heidi’s European expansion, nor does it specify the terms or deployment conditions of the $240 million growth investment. It is also unclear how quickly regulatory work will translate into approved advanced features or measurable adoption across health systems.
- Monitor next
- Watch for Heidi announcing named German leadership hires, DACH headcount growth, or specific European/UK regulatory clearances for advanced clinical features.
Analytical support, not advice — assumptions and open questions stated above.